{"DataElement":{"publicId":"2005421","version":"2","preferredName":"CTC Adverse Event Second Malignant Neoplasm Grade","preferredDefinition":"in CTC category Secondary Malignancy (excludes metastasis from initial primary), assessment of the severity of an unlisted adverse event type using a graded scale.","longName":"CTC_AE_SECMALG_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2192369","version":"1","preferredName":"CTC Adverse Event Secondary Malignant Neoplasm","preferredDefinition":"information related to the CTC adverse event of a secondary malignancy.","longName":"CTC_AE_SECMALG","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2192367","version":"1","preferredName":"Secondary Malignant Neoplasm","preferredDefinition":"Cancer that has spread from the organ in which it first appeared to another organ. For example, breast cancer cells may spread (metastasize) to the lungs and cause the growth of a new tumor. When this happens, the disease is called metastatic breast cancer, and the tumor in the lungs is called a secondary tumor. Also called secondary tumor.","longName":"Secondary Malignant Neoplasm","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Secondary Malignant Neoplasm","conceptCode":"C4968","definition":"A malignant neoplasm that arises from a pre-existing lower grade lesion, or as a result of a primary lesion that has spread to secondary sites, or due to a complication of a cancer treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7C09E36-190C-2AD7-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-19","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7C09E36-1912-2AD7-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2017621","version":"3","preferredName":"CTC Adverse Event Second Malignant Neoplasm Grade","preferredDefinition":"in CTC category Secondary Malignancy (excludes metastasis from initial primary), assessment of the severity of an unlisted adverse event type using a graded scale.","longName":"CTC_AE_SECMALG_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5","valueDescription":"Death","ValueMeaning":{"publicId":"2561497","version":"1","preferredName":"Death","longName":"2561497","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dead","conceptCode":"C28554","definition":"The cessation of life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BD46-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-05","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1DB2517-7AE7-4880-E034-0003BA12F5E7","beginDate":"2002-10-11","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-26","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Non-life-threatening basal or squamous cell carcinoma of the skin","ValueMeaning":{"publicId":"2568121","version":"1","preferredName":"Non-life-threatening basal or squamous cell carcinoma of the skin","longName":"2568121","preferredDefinition":"Non-life-threatening basal or squamous cell carcinoma of the skin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D726-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-26","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-26","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1DA7C05-571C-4673-E034-0003BA12F5E7","beginDate":"2004-01-26","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-26","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"Solid tumor, leukemia or lymphoma","ValueMeaning":{"publicId":"2568122","version":"1","preferredName":"Solid tumor, leukemia or lymphoma","longName":"2568122","preferredDefinition":"Solid tumor, leukemia or lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D727-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-26","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-26","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D1DA7C05-5720-4673-E034-0003BA12F5E7","beginDate":"2004-01-26","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-26","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D1DB2517-7AE3-4880-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-01-26","endDate":null,"createdBy":"PWEST","dateCreated":"2004-01-26","modifiedBy":"MAESKEB","dateModified":"2009-05-06","changeDescription":"updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]}],"AlternateNames":[{"name":"2005421","type":"HISTORICAL_CDE_ID","context":"CTEP"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Alternate Question Text","description":"Secondary Malignancy-Other Grade","url":null,"context":"CTEP"},{"name":"1-COMMENT","type":"COMMENT","description":"(excludes metastasis from initial primary)","url":null,"context":"CTEP"},{"name":"CDUS_SOURCE","type":"DATA_ELEMENT_SOURCE","description":"Use CTC v2.0 or CTCAE v3.0 (as determined by CTEP) for reporting to Clinical Data Update System (CDUS) v3.0 Release 2","url":"http://ctep.cancer.gov/reporting/cdus.html","context":"CTEP"},{"name":"CTCAE_SOURCE","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"},{"name":"CTC Adverse Event Secondary M","type":"Preferred Question Text","description":"CTC Adverse Event Secondary Malignancy (excludes metastasis from initial primary)-Other (Specify) Grade","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B4EEBE0A-A906-6DB1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-23","endDate":null,"createdBy":"PWEST","dateCreated":"2003-01-23","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"updated for ISO compliance; updated to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}